Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Fineline Cube Sep 10, 2026
Company Drug

MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials

Fineline Cube Jul 28, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase...

Company Deals

Pharmaniaga Berhad and CSPC Pharmaceutical Group Broaden Collaboration in Pharma and Biopharma

Fineline Cube Jul 27, 2023

Malaysia-based pharmaceutical company Pharmaniaga Berhad has announced the signing of a comprehensive collaboration with China’s...

Company

Thermo Fisher Scientific Reports Q2 2023 Revenue Dip, Adjusts Full-Year Forecast

Fineline Cube Jul 27, 2023

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has released its financial results...

Company Deals

AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research

Fineline Cube Jul 27, 2023

AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research...

Company

GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance

Fineline Cube Jul 27, 2023

UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the...

Company Drug

Everest Medicines Launches Xerava Antibiotic in China, Marking Commercial Milestone

Fineline Cube Jul 27, 2023

Everest Medicines (HKG: 1952) has announced the commercial launch of its Xerava (eravacycline) antibiotic in...

Company Drug

Jiangsu Recbio’s Shingles Vaccine REC610 Accepted for Review by China’s NMPA

Fineline Cube Jul 27, 2023

Jiangsu Recbio Technology Co., Ltd, a China-based company, has announced that the National Medical Products...

Company Deals

Mirxes Holding Company Secures USD 50 Million in Series D Financing for RNA Technology

Fineline Cube Jul 27, 2023

Mirxes Holding Company Ltd, a Singapore-headquartered RNA technology company specializing in blood-based miRNA test kit...

Company Drug

Shanghai Henlius Completes Phase I/II Study for Anti-VEGF mAb HLX04-O in Wet AMD

Fineline Cube Jul 27, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary, Shanghai Henlius Biotech, Inc....

Company Deals

Innovent Biologics’ Altruist Biologics Partners with Longbio Pharma in RMB 500 Million Deal

Fineline Cube Jul 27, 2023

Altruist Biologics, the Contract Development and Manufacturing Organization (CDMO) unit of China-based Innovent Biologics, Inc. (HKG:...

Company Drug

SSY Group Ltd Receives NMPA Approval for Stiripentol Dry Suspension for Dravet Syndrome

Fineline Cube Jul 27, 2023

China-based SSY Group Ltd (HKG: 2005) has announced that it has received marketing approval from...

Company Drug

Novo Nordisk’s Turoctocog Alfa Pegol for Hemophilia A Accepted for Review by China’s CDE

Fineline Cube Jul 26, 2023

The Center for Drug Evaluation (CDE) in China has indicated on its website that the...

Company Medical Device

Sisram Medical’s Alma Veil Launches in the US for Vascular Lesion Treatment

Fineline Cube Jul 26, 2023

Alma Lasers, a subsidiary of Sisram Medical (HKG: 1696), has announced the commercial availability of...

Company Drug

AstraZeneca’s Eplontersen Gains Tacit Approval from CDE for ATTR-CM Clinical Study

Fineline Cube Jul 26, 2023

The Center for Drug Evaluation (CDE) website indicates that UK pharmaceutical major AstraZeneca’s (AZ, NASDAQ:...

Company Deals

Kanova Biopharma Secures Over RMB 100 Million in Financing for Autoimmune and Oncology Pipeline

Fineline Cube Jul 26, 2023

Kanova Biopharma, a Suzhou-based developer of antibodies focused on autoimmune diseases and oncology, has reportedly...

Company Drug

Boehringer Ingelheim Gets NMPA Approval for Phase II Study of BI 764532 in SCLC

Fineline Cube Jul 26, 2023

Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical Products...

Company Drug

HanchorBio’s HCB101 Receives WFDA Approval for Multi-Region Clinical Study

Fineline Cube Jul 26, 2023

Taiwan-based HanchorBio has announced that it has received approval from the Taiwan Food and Drug...

Company Deals

Sosei Heptares Acquires Idorsia’s Korea and Japan Units in JPY 65 Billion Deal

Fineline Cube Jul 26, 2023

Japan-based Sosei Group Corporation (TYO: 4565) has announced that its subsidiary, Sosei Heptares, has acquired...

Company Drug

InnoCare Pharma’s ICP-723 Receives NMPA Approval for Pediatric Clinical Study

Fineline Cube Jul 26, 2023

Beijing InnoCare Pharma (HKG: 9969), a China-based biotech company specializing in cancer and autoimmune diseases,...

Company Drug

Boehringer Ingelheim and Eli Lilly’s Jardiance Approved by EC for Chronic Kidney Disease

Fineline Cube Jul 26, 2023

Germany-based Boehringer Ingelheim and its US partner Eli Lilly & Co., (NYSE: LLY), have reported...

Posts pagination

1 … 550 551 552 … 719

Recent updates

  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
  • Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers
  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Company Drug

NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.